Work with thought leaders and academic experts in Disease Modeling

Companies can greatly benefit from collaborating with academic researchers specializing in Disease Modeling. These experts possess in-depth knowledge and skills in analyzing and predicting the spread of diseases. By partnering with them, companies can enhance their research capabilities, gain valuable insights into disease dynamics, and develop effective strategies for disease prevention and control. Disease Modeling experts can also assist in optimizing healthcare resource allocation, identifying high-risk populations, and evaluating the impact of interventions. Their expertise can be applied across various industries, including pharmaceuticals, public health, healthcare systems, and policy development.

Researchers on NotedSource with backgrounds in Disease Modeling include Jeffrey Townsend, Osaye Fadekemi, PhD, Matthew Scarnati, and Pinar Mesci.

Osaye Fadekemi, PhD

4 Years Experience
Assistant Professor of Mathematics at Alabama State University with expertise in Graph Theory and Network Modeling
Education

University of Johannesburg

Doctor of Philosophy, Department of Pure and Applied Mathematics / July, 2019

Auckland Park

University of KwaZulu-Natal

Master of Science, School of Mathematics, Statistics and Computer Science / March, 2015

Durban

African Institute For Mathematical Sciences Ghana

Master of Science, Mathematical Sciences / June, 2013

Biriwa
Experience

Auburn University Auburn

Visiting Asisitant Professor / August, 2019May, 2021

Alabama State University

Assistant Professor / June, 2021Present

Most Relevant Research Expertise
Disease Modeling
Other Research Expertise (11)
Graph Theory
Network Modeling
Discrete Mathematics and Combinatorics
Theoretical Computer Science
Applied Mathematics
And 6 more
About
Dr Fadekemi Janet Osaye is a mathematician whose primary research interest is in graph theory and network modeling. In particular, she is interested in distance measures in graphs and their applications to solving many real-world problems. Her interest in discrete mathematics was inspired by her research project carried out at AIMS Ghana. She has published several articles in reputable journals and has presented in several conferences across the globe. In 2019, she became the first black female to be awarded a PhD in Mathematics by the University of Johannesburg, South Africa, in its 116 years of its existence. Since June 2021, she has been an Assistant Professor of Mathematics at Alabama State University and was previously a Visiting Assistant Professor at Auburn University. She is the founder of GirlsMatics Foundation, a STEM non-governmental organisation for girls in Nigeria which was motivated by her involvement with AIMS Ghana’s outreach programs for high school students in Biriwa, Ghana. She is also the co-founder of FadNna Partners, an analytics and management firm based in Lagos, Nigeria.

See Full Profile

Matthew Scarnati

Old Bridge, New Jersey, United States of America
6 Years Experience
Neuroscientist driving preclinical drug development programs to combat neurological disease.
Education

Rutgers University - Busch Campus

PhD, Cell Biology and Neuroscience / December, 2017

Piscataway, New Jersey, United States of America

UMDNJ-School of Osteopathic Medicine Department of Molecular Biology

PhD Student , Molecular Biology / May, 2013

Stratford, New Jersey, United States of America

Stockton University

BS Biochemistry and Molecular Biology, Biochemsitry and Molecular Biology / May, 2009

Galloway, New Jersey, United States of America
Experience

Rutgers Robert Wood Johnson Medical School New Brunswick

Postdoctoral Fellow / January, 2018January, 2021

PTC Therapeutics, Inc.

Scientist II / January, 2022January, 2024

Eternity Biosciences INC

Senior Research Investigator / May, 2021November, 2021

Most Relevant Research Expertise
Disease Modeling
Other Research Expertise (4)
Neuroscience
Stem Cell Biology
Electrophysiology
Neuropsychiatric Disorders
About
I am a seasoned and perseverent pre-clinical drug development neuroscientist with over 12 years of research experience covering NEUROSCIENCE, Biochemistry, Molecular and Cellular Biology, Synaptic Physiology and Stem Cell Biology. My "never give up" attitude and vast experience in many disciplines adopts me the ability to address scientific questions in creative and unique ways. I have experience in pre-clinical small molecule drug development to support chemistry SAR to identify lead therapeutic candidates for neurology related targets. Experience in design, optimization and execution of both cell based and biochemical assays. I can provide expertise in synaptic physiology, and neuropsychiatric disease modeling. I have comprehensively studied the biological basis of addiction utilizing human stem cell biology and cellular reprogramming techniques. I am well versed in cutting edge induced neuronal (iN) cell technology. My main roles at PTC as a preclinical drug development Neuroscientist: -Provide subject matter expertise and leadership in the expansion of neuroscience and neurological disease understanding -Design and execute high-throughput in-vitro cell-based assays to screen 100s of small molecules to assist in driving chemistry SAR -Validation of new drug targets accomplished through elegant experimental design (both cell-based and biochemical) -My main focus was elucidating the mechanism(s) of action of one of PTCs lead small molecule drug candidates for a rare neurological disorder -Comprehensively screened primary mouse neuronal cultures (as well as human cell lines) to identify disease specific biomarkers for pharmacodynamic studies -Mentored and trained associate level scientists on both the technical and conceptual framework of our teams small molecule pipeline -Translating in-vitro cell based findings into in-vivo rodent models to better understand the PK/PD relationship of our lead small molecule -Team lead for a gene-therapy focused project to combat a devastating rare pediatric indication ➢ Scientific communication is a great strength of mine. My experience has provided me with excellent presentation skills and the ability to convey my work to diverse audiences. https://www.ncbi.nlm.nih.gov/myncbi/matthew.scarnati.1/bibliography/public/ EMAIL: matthewscarnati@gmail.com SKILLS: Pre\-Clinical Drug Discovery I Electrophysiology \| Human Stem Cell Biology \| Mammalian Tissue Culture \| Cell Signaling Pathways \| Confocal Microscopy \| Protein Purification and Expression \| qPCR \| Cellular Assays \| Science Writing \| Problem Solving \| ELISA

See Full Profile

Example Disease Modeling projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on Disease Modeling?

Optimizing Vaccine Distribution

A Disease Modeling expert can develop models to optimize the distribution of vaccines, considering factors such as population density, disease prevalence, and vaccine supply. This can help companies ensure efficient and equitable vaccine distribution, especially during outbreaks or pandemics.

Predicting Disease Outbreaks

By analyzing historical data and using advanced modeling techniques, a Disease Modeling expert can predict disease outbreaks and identify potential hotspots. This information can assist companies in implementing proactive measures to prevent and control the spread of diseases.

Assessing Intervention Strategies

Disease Modeling experts can evaluate the effectiveness of different intervention strategies, such as social distancing measures, vaccination campaigns, or targeted interventions. This helps companies make informed decisions and allocate resources efficiently to mitigate the impact of diseases.

Simulating Healthcare System Capacity

Through simulation modeling, Disease Modeling experts can assess the capacity and resilience of healthcare systems in handling disease outbreaks. This enables companies to identify potential bottlenecks, optimize resource allocation, and plan for surge capacity.

Evaluating Economic Impact

Collaborating with a Disease Modeling expert allows companies to assess the economic impact of diseases on various sectors. This includes estimating productivity losses, healthcare costs, and potential disruptions to supply chains, enabling companies to develop strategies for risk mitigation and business continuity.